ARTICLE | Clinical News
Boehringer places clinical hold on BACE inhibitor
February 27, 2015 2:10 AM UTC
Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) lost $3 to $10.28 in after-hours trading Thursday after it said partner Boehringer Ingelheim GmbH (Ingelheim, Germany) voluntarily placed a temporary clinical hold on a German Phase I multiple ascending-dose trial of BI1181181.
The partners are developing the beta-site APP-cleaving enzyme 1 ( BACE1) inhibitor to treat and prevent Alzheimer's disease. The hold was placed to investigate skin reactions seen in an undisclosed number of patients during the trial. ...